# Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

> **NCT06779539** · PHASE2 · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 33 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Ensartinib

## Key facts

- **NCT ID:** NCT06779539
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2028-06-12
- **Final completion:** 2030-12-12
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06779539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06779539, "Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT06779539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*